# DEXCOM INC

Summary updated: 2026-10-02T08:44:37.4218Z
Canonical: https://finbar.com/research/companies/dexcom

## Overview

Dexcom, Inc. is a medical-device company focused on continuous glucose monitoring (CGM) for diabetes and metabolic-health management. Its products include CGM systems such as Dexcom G7 and G7 15 Day, as well as Stelo, an over-the-counter glucose biosensor. The company’s stated mission is “Empowering People to Take Control of Health.” [1](https://app.finbar.com/go?id=P53710509)[2](https://app.finbar.com/go?id=P94647663)[3](https://app.finbar.com/go?id=P67075618)

Founded in 1999 and headquartered in San Diego, Dexcom serves customers in the United States and international markets. It reported $4.662 billion in revenue for 2025, including $3.335 billion in U.S. revenue and $1.327 billion internationally. [2](https://app.finbar.com/go?id=P94647663)[4](https://app.finbar.com/go?id=T6400435)[5](https://app.finbar.com/go?id=T5826161) Dexcom’s company profile reports more than 8,000 employees worldwide. [6](https://www.dexcom.com/en-au/about-us)
[1](https://app.finbar.com/go?id=P53710509)[2](https://app.finbar.com/go?id=P94647663)[3](https://app.finbar.com/go?id=P67075618)[4](https://app.finbar.com/go?id=T6400435)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[6](https://www.dexcom.com/en-au/about-us)

## Products & services

Dexcom’s products center on continuous glucose monitoring (CGM). Its Dexcom G7 is an all-in-one wearable sensor and transmitter for people with diabetes aged 2 and older. It provides glucose readings every five minutes, has a 10-day wear period and 30-minute warmup, and offers customizable high- and low-glucose alerts, including predictive low alerts. Fingersticks are not required for calibration or treatment decisions, except when symptoms do not match the sensor readings. [7](https://app.finbar.com/go?id=P40409480)[8](https://app.finbar.com/go?id=P21901351)[9](https://app.finbar.com/go?id=P105727765)[10](https://app.finbar.com/go?id=P93090110)[11](https://app.finbar.com/go?id=P33130020)[12](https://app.finbar.com/go?id=P45057124)[13](https://app.finbar.com/go?id=P89183523) Dexcom G7 15 Day, authorized in the U.S. for adults with diabetes, offers up to 15.5 days of wear and a 60-minute warmup; the company reports an overall MARD of 8.0%. [14](https://app.finbar.com/go?id=P45073015)[15](https://app.finbar.com/go?id=P74187573) Stelo is an over-the-counter glucose biosensor for adults with prediabetes or type 2 diabetes who do not use insulin; it provides up to 15 days of wear plus a 12-hour grace period through an app. [2](https://app.finbar.com/go?id=P94647663)[16](https://provider.dexcom.com/products/stelo) Dexcom ONE+ is a CGM system marketed in Europe, including for people aged 2 and older. [17](https://app.finbar.com/go?id=P5336759)

Related software and services include Dexcom Clarity, cloud-based CGM data reporting, and Share/Follow, which lets users share glucose data and alerts with designated followers. [3](https://app.finbar.com/go?id=P67075618)[18](https://app.finbar.com/go?id=P39039777) Dexcom’s CGM systems also integrate with compatible insulin pumps, smart insulin pens, watches, and digital-health applications; some pump integrations support semi-automated insulin delivery. [19](https://app.finbar.com/go?id=P21728576)[20](https://app.finbar.com/go?id=P86783299) Dexcom reports one operating and reportable segment, with revenue from disposable sensors and reusable hardware; it does not disclose revenue percentages by individual product family. [21](https://app.finbar.com/go?id=P83753986)
[7](https://app.finbar.com/go?id=P40409480)[8](https://app.finbar.com/go?id=P21901351)[9](https://app.finbar.com/go?id=P105727765)[10](https://app.finbar.com/go?id=P93090110)[11](https://app.finbar.com/go?id=P33130020)[12](https://app.finbar.com/go?id=P45057124)[13](https://app.finbar.com/go?id=P89183523)[14](https://app.finbar.com/go?id=P45073015)[15](https://app.finbar.com/go?id=P74187573)[2](https://app.finbar.com/go?id=P94647663)[16](https://provider.dexcom.com/products/stelo)[17](https://app.finbar.com/go?id=P5336759)[3](https://app.finbar.com/go?id=P67075618)[18](https://app.finbar.com/go?id=P39039777)[19](https://app.finbar.com/go?id=P21728576)[20](https://app.finbar.com/go?id=P86783299)[21](https://app.finbar.com/go?id=P83753986)[16](https://provider.dexcom.com/products/stelo)

## Geographic presence

Dexcom is headquartered in San Diego, California. Its FY2025 operating locations included corporate, research and development, and manufacturing functions in San Diego; manufacturing in Mesa, Arizona, and Penang, Malaysia; and a manufacturing facility under construction in Athenry, Ireland. [22](https://app.finbar.com/go?id=P60678974) [23](https://app.finbar.com/go?id=P76842441) [24](https://app.finbar.com/go?id=P40140144)

In FY2025, revenue was $3,334.9 million in the United States (71.5%) and $1,327.1 million internationally (28.5%), out of $4,662.0 million total. The reported geographic breakdown is U.S. versus International, rather than by individual country. [5](https://app.finbar.com/go?id=T5826161) Dexcom’s official global directory includes market pages for Canada, Australia, Japan, the United Kingdom, and other European markets. [25](https://www.dexcom.com/en-us/global)
[22](https://app.finbar.com/go?id=P60678974)[23](https://app.finbar.com/go?id=P76842441)[24](https://app.finbar.com/go?id=P40140144)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[25](https://www.dexcom.com/en-us/global)

## Business segments

Dexcom reports one operating and reportable segment, rather than separate product or regional segments. It manages the business on a consolidated basis; the segment sells disposable sensors and reusable transmitters and receivers and accounts for all consolidated revenue. The company does not disclose separate revenue contributions for those product categories. [26](https://app.finbar.com/go?id=P145057581)[21](https://app.finbar.com/go?id=P83753986)[27](https://app.finbar.com/go?id=T4471723)

Geography and sales channel are disclosed as revenue breakdowns, not as reportable segments. In FY2025, approximately 72% of revenue came from the U.S. ($3,334.9 million) and 28% from international markets ($1,327.1 million), out of $4,662.0 million total. [5](https://app.finbar.com/go?id=T5826161) In the same year, distributor sales were $3,959.0 million and direct sales were $703.0 million. [5](https://app.finbar.com/go?id=T5826161) The latest available filing in the research results is the Q2 2026 Form 10-Q; FY2025 is the latest annual reporting year identified.
[26](https://app.finbar.com/go?id=P145057581)[21](https://app.finbar.com/go?id=P83753986)[27](https://app.finbar.com/go?id=T4471723)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)[5](https://app.finbar.com/go?id=T5826161)

## Company history

Founded in San Diego in 1999, Dexcom received FDA approval for and commercialized its first continuous glucose monitoring product in 2006. The company’s product milestones included the SEVEN system in 2007, G4 PLATINUM in 2012, G5 Mobile in 2016 and G6 in 2018. [28](https://www.dexcom.com/en-GB/about-dexcom)[29](https://app.finbar.com/go?id=P64731181)

Dexcom expanded into diabetes-data software with its 2012 agreement to acquire SweetSpot, and into automated insulin-delivery technology through its 2018 acquisition of TypeZero Technologies. In 2015, Kevin Sayer became president and CEO, succeeding Terry Gregg, who became executive chairman. [30](https://www.businesswire.com/news/home/20120223006633/en/DexCom-Announces-Acquisition-SweetSpot-Diabetes-Care)[31](https://investors.dexcom.com/news/news-details/2018/Dexcom-Acquires-TypeZero-Technologies/default.aspx)[32](https://investors.dexcom.com/news/news-details/2015/Kevin-Sayer-Assumes-Role-of-President-and-Chief-Executive-Officer-Terry-Gregg-Transitions-to-Role-of-Executive-Chairman/default.aspx)

The G7 system received FDA authorization in December 2022 and launched in the United States in 2023, followed by international rollout. In 2024, Dexcom launched Stelo, its first over-the-counter glucose biosensor. [3](https://app.finbar.com/go?id=P67075618)[33](https://investors.dexcom.com/news/news-details/2023/Dexcom-and-Nick-Jonas-Make-Super-Bowl-Magic-to-Launch-New-Dexcom-G7-Continuous-Glucose-Monitoring-System/default.aspx)[29](https://app.finbar.com/go?id=P64731181)[34](https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx)

In 2026, Jake Leach assumed the president and CEO role, with Sayer becoming executive chairman. [35](https://investors.dexcom.com/news/news-details/2026/Dexcom-Enters-Next-Era-of-Continued-Innovation-With-Jake-Leach-as-President-and-Chief-Executive-Officer/default.aspx)
[29](https://app.finbar.com/go?id=P64731181)[3](https://app.finbar.com/go?id=P67075618)[28](https://www.dexcom.com/en-GB/about-dexcom)[30](https://www.businesswire.com/news/home/20120223006633/en/DexCom-Announces-Acquisition-SweetSpot-Diabetes-Care)[31](https://investors.dexcom.com/news/news-details/2018/Dexcom-Acquires-TypeZero-Technologies/default.aspx)[32](https://investors.dexcom.com/news/news-details/2015/Kevin-Sayer-Assumes-Role-of-President-and-Chief-Executive-Officer-Terry-Gregg-Transitions-to-Role-of-Executive-Chairman/default.aspx)[33](https://investors.dexcom.com/news/news-details/2023/Dexcom-and-Nick-Jonas-Make-Super-Bowl-Magic-to-Launch-New-Dexcom-G7-Continuous-Glucose-Monitoring-System/default.aspx)[34](https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx)[35](https://investors.dexcom.com/news/news-details/2026/Dexcom-Enters-Next-Era-of-Continued-Innovation-With-Jake-Leach-as-President-and-Chief-Executive-Officer/default.aspx)

## Sources

1. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53710509)
2. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P94647663)
3. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P67075618)
4. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T6400435)
5. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T5826161)
6. [www.dexcom.com](https://www.dexcom.com/en-au/about-us)
7. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P40409480)
8. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P21901351)
9. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P105727765)
10. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P93090110)
11. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P33130020)
12. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P45057124)
13. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P89183523)
14. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P45073015)
15. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P74187573)
16. [provider.dexcom.com](https://provider.dexcom.com/products/stelo)
17. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P5336759)
18. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P39039777)
19. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P21728576)
20. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P86783299)
21. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P83753986)
22. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P60678974)
23. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P76842441)
24. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P40140144)
25. [www.dexcom.com](https://www.dexcom.com/en-us/global)
26. [DEXCOM INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145057581)
27. [DEXCOM INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T4471723)
28. [www.dexcom.com](https://www.dexcom.com/en-GB/about-dexcom)
29. [DEXCOM INC — Full financial report (2026 Q 1)](https://app.finbar.com/go?id=P64731181)
30. [www.businesswire.com](https://www.businesswire.com/news/home/20120223006633/en/DexCom-Announces-Acquisition-SweetSpot-Diabetes-Care)
31. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2018/Dexcom-Acquires-TypeZero-Technologies/default.aspx)
32. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2015/Kevin-Sayer-Assumes-Role-of-President-and-Chief-Executive-Officer-Terry-Gregg-Transitions-to-Role-of-Executive-Chairman/default.aspx)
33. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2023/Dexcom-and-Nick-Jonas-Make-Super-Bowl-Magic-to-Launch-New-Dexcom-G7-Continuous-Glucose-Monitoring-System/default.aspx)
34. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx)
35. [investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Enters-Next-Era-of-Continued-Innovation-With-Jake-Leach-as-President-and-Chief-Executive-Officer/default.aspx)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.